Index RUT P/E - EPS (ttm) -2.40 Insider Own 48.67% Shs Outstand 49.18M Perf Week 5.86%
Market Cap 534.87M Forward P/E - EPS next Y -2.10 Insider Trans 16.92% Shs Float 36.17M Perf Month -23.26%
Income -117.50M PEG - EPS next Q -0.55 Inst Own 47.76% Short Float 15.41% Perf Quarter -16.04%
Sales 0.00M P/S - EPS this Y 7.03% Inst Trans -4.92% Short Ratio 5.52 Perf Half Y 273.89%
Book/sh 5.56 P/B 1.37 EPS next Y 5.99% ROA -27.59% Short Interest 5.57M Perf Year 46.81%
Cash/sh 3.52 P/C 2.16 EPS next 5Y - ROE -36.41% 52W Range 1.28 - 16.24 Perf YTD 15.00%
Dividend Est. - P/FCF - EPS past 5Y -209.81% ROI -33.05% 52W High -53.26% Beta 0.89
Dividend TTM - Quick Ratio 10.85 Sales past 5Y -39.65% Gross Margin - 52W Low 492.97% ATR (14) 0.84
Dividend Ex-Date - Current Ratio 10.85 EPS Y/Y TTM 9.59% Oper. Margin 0.00% RSI (14) 42.54 Volatility 7.43% 8.27%
Employees 150 Debt/Eq 0.32 Sales Y/Y TTM - Profit Margin - Recom 1.10 Target Price 19.25
Option/Short Yes / Yes LT Debt/Eq 0.30 EPS Q/Q 15.29% Payout - Rel Volume 0.72 Prev Close 6.68
Sales Surprise - EPS Surprise 1.84% Sales Q/Q - Earnings Mar 21 AMC Avg Volume 1.01M Price 7.59
SMA20 -5.34% SMA50 -26.06% SMA200 40.61% Trades
Volume 624,082 Change 13.62%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-22-24 Downgrade Raymond James
Strong Buy → Outperform
$13 → $16
Dec-22-22 Downgrade Oppenheimer
Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity
Buy
$25
Jul-28-22 Initiated Needham
Buy
$26
Jul-18-22 Initiated SVB Leerink
Outperform
$30
Mar-11-22 Initiated Raymond James
Outperform
$17
Mar-08-22 Initiated H.C. Wainwright
Buy
$25
Jan-06-22 Initiated William Blair
Outperform
Nov-18-21 Initiated SMBC Nikko
Outperform
$50
Jul-16-21 Initiated Oppenheimer
Outperform
$75
Aug-04-20 Initiated Stifel
Buy
$41
Aug-04-20 Initiated Mizuho
Buy
$34
Aug-04-20 Initiated Evercore ISI
Outperform
$55
Aug-04-20 Initiated Cowen
Outperform
Show Previous Ratings
Apr-03-24 04:02PM
Mar-25-24 04:06PM
(Investor's Business Daily) +17.60%
06:30AM
Mar-23-24 05:31AM
Mar-22-24 04:03PM
(Investor's Business Daily) -31.28%
09:18AM
Loading…
09:18AM
Mar-21-24 10:54PM
04:01PM
Mar-19-24 07:29AM
Feb-29-24 06:30AM
Feb-28-24 08:01AM
Feb-20-24 04:19PM
Feb-08-24 09:32AM
Feb-06-24 12:50PM
Feb-05-24 12:41PM
08:00AM
Loading…
Feb-04-24 08:00AM
Jan-09-24 10:25AM
Dec-09-23 08:31PM
Dec-08-23 12:00PM
Nov-14-23 03:56PM
Nov-09-23 04:02PM
11:38AM
Nov-07-23 08:02AM
Oct-25-23 02:06PM
Oct-18-23 10:47AM
01:18AM
Oct-17-23 08:17PM
(FierceBiotech.com) +112.16%
11:47AM
07:01AM
Oct-16-23 04:01PM
03:07PM
Loading…
Oct-02-23 03:07PM
Aug-10-23 07:01AM
Aug-03-23 08:02AM
Jul-31-23 06:30PM
Jul-05-23 04:02PM
Jun-28-23 09:35AM
Jun-27-23 01:02PM
07:01AM
Jun-26-23 04:01PM
Jun-15-23 09:55AM
Jun-10-23 10:47AM
May-11-23 04:02PM
04:01PM
May-09-23 07:15AM
May-07-23 12:50PM
Apr-17-23 05:01PM
Apr-12-23 09:06PM
Apr-11-23 09:46AM
Mar-30-23 04:01PM
Mar-16-23 04:01PM
Feb-17-23 05:35AM
Feb-09-23 08:02AM
Jan-09-23 04:30PM
Dec-05-22 07:02AM
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
09:55AM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
10:18AM
Apr-25-22 11:19PM
06:04PM
05:44PM
(American City Business Journals)
04:09PM
(Investor's Business Daily)
04:01PM
03:52PM
10:49AM
08:34AM
08:19AM
07:12AM
07:00AM
Apr-22-22 04:10PM
Apr-17-22 08:54AM
Apr-08-22 01:25PM
07:58AM
Apr-04-22 12:00PM
Mar-29-22 08:02AM
Mar-22-22 10:00AM
Mar-17-22 04:02PM
Mar-08-22 04:35PM
Mar-01-22 11:00AM
(American City Business Journals)
Feb-10-22 08:02AM
Jan-05-22 06:56AM
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Mar 27 '24 Buy 10.00 3,000,000 30,000,000 10,050,818 Mar 29 05:38 PM George Simeon Director Mar 27 '24 Buy 10.00 2,000,000 20,000,000 1,548,341 Mar 28 04:30 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Option Exercise 3.89 6,763 26,308 88,339 Mar 05 04:26 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Sale 12.51 8,367 104,671 79,972 Mar 05 04:26 PM Trager James Chief Scientific Officer Feb 12 '24 Sale 12.00 4,143 49,716 149,415 Feb 14 09:12 PM HASTINGS PAUL J Chief Executive Officer Jan 16 '24 Sale 8.74 9,697 84,752 390,507 Jan 18 04:40 PM Trager James Chief Scientific Officer Jan 16 '24 Sale 8.74 4,560 39,854 153,558 Jan 18 04:43 PM Hager Alicia J. Chief Legal Officer Jan 16 '24 Sale 8.74 4,554 39,802 107,942 Jan 18 04:38 PM Shook David Chief Medical Officer Jan 16 '24 Sale 8.74 3,552 31,044 114,980 Jan 18 04:45 PM Brandenberger Ralph Chief Technical Officer Jan 16 '24 Sale 8.74 2,512 21,955 81,576 Jan 18 04:40 PM Shook David Chief Medical Officer Aug 21 '23 Sale 1.83 1,331 2,436 60,532 Aug 23 04:11 PM HASTINGS PAUL J Chief Executive Officer Jun 20 '23 Sale 4.85 1,704 8,264 313,402 Jun 22 04:20 PM Hager Alicia J. Chief Legal Officer Jun 20 '23 Sale 4.85 701 3,400 56,496 Jun 22 04:23 PM Mahmood Nadir See Remarks Jun 20 '23 Sale 4.85 526 2,551 85,776 Jun 22 04:21 PM Trager James Chief Scientific Officer Jun 20 '23 Sale 4.85 439 2,129 100,118 Jun 22 04:26 PM Shook David Chief Medical Officer Jun 20 '23 Sale 4.85 439 2,129 61,863 Jun 22 04:22 PM Brandenberger Ralph Chief Technical Officer Jun 20 '23 Sale 4.85 221 1,072 28,088 Jun 22 04:25 PM
Index RUT P/E 34.65 EPS (ttm) 0.78 Insider Own 2.87% Shs Outstand 46.48M Perf Week 3.78%
Market Cap 1.25B Forward P/E 7.59 EPS next Y 3.54 Insider Trans -8.20% Shs Float 45.19M Perf Month -5.72%
Income 41.95M PEG 3.33 EPS next Q 0.62 Inst Own 106.20% Short Float 7.63% Perf Quarter -17.52%
Sales 674.98M P/S 1.85 EPS this Y -1.26% Inst Trans 2.36% Short Ratio 6.85 Perf Half Y -3.24%
Book/sh 18.72 P/B 1.44 EPS next Y 27.67% ROA 2.58% Short Interest 3.45M Perf Year -42.32%
Cash/sh 5.99 P/C 4.49 EPS next 5Y 10.40% ROE 5.10% 52W Range 25.33 - 48.60 Perf YTD -20.33%
Dividend Est. - P/FCF 8.96 EPS past 5Y - ROI 2.92% 52W High -44.69% Beta 0.77
Dividend TTM - Quick Ratio 4.17 Sales past 5Y 15.46% Gross Margin 64.15% 52W Low 6.12% ATR (14) 0.90
Dividend Ex-Date - Current Ratio 5.24 EPS Y/Y TTM 155.39% Oper. Margin 12.94% RSI (14) 46.61 Volatility 3.32% 3.23%
Employees 712 Debt/Eq 0.67 Sales Y/Y TTM 1.22% Profit Margin 6.22% Recom 1.20 Target Price 45.30
Option/Short Yes / Yes LT Debt/Eq 0.65 EPS Q/Q 316.94% Payout 0.00% Rel Volume 0.55 Prev Close 26.25
Sales Surprise 0.35% EPS Surprise 0.76% Sales Q/Q 5.40% Earnings May 07 AMC Avg Volume 502.96K Price 26.88
SMA20 -0.45% SMA50 -5.98% SMA200 -13.92% Trades
Volume 236,549 Change 2.40%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-24 Resumed JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated Raymond James
Outperform
$42
Aug-03-23 Upgrade TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed Jefferies
Buy
$66
Jan-03-22 Resumed JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed JP Morgan
Neutral
$70
Apr-09-21 Initiated Berenberg
Buy
$93
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated Needham
Buy
$52 → $64
May-27-20 Initiated Guggenheim
Neutral
Apr-07-20 Initiated Northland Capital
Outperform
$50
Mar-20-20 Upgrade SVB Leerink
Mkt Perform → Outperform
$44
Feb-24-20 Reiterated H.C. Wainwright
Buy
$60 → $63
Jan-24-20 Initiated SunTrust
Buy
Jan-23-20 Initiated SunTrust
Buy
Show Previous Ratings
Apr-30-24 08:00AM
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
Mar-13-24 07:00AM
11:55PM
Loading…
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
Loading…
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
Loading…
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
(Thomson Reuters StreetEvents)
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Jan-05-23 04:30PM
Jan-04-23 08:00AM
Dec-20-22 10:06AM
Dec-13-22 08:00AM
Nov-18-22 01:38PM
Nov-17-22 08:05AM
Nov-14-22 08:00AM
Nov-09-22 05:14AM
Nov-08-22 08:00AM
Nov-04-22 10:54AM
Nov-03-22 09:15AM
08:00AM
Nov-01-22 10:01AM
Oct-27-22 10:02AM
Oct-20-22 08:00AM
Oct-15-22 08:34AM
Oct-13-22 08:00AM
Oct-07-22 02:10PM
(Investor's Business Daily)
Sep-27-22 08:00AM
Sep-21-22 06:04PM
10:08AM
08:00AM
Sep-20-22 08:00AM
Sep-13-22 08:00AM
Sep-08-22 10:42AM
Sep-07-22 11:07AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM WINSTON ROY Chief Medical Officer Aug 02 '23 Sale 34.88 509 17,751 52,440 Aug 04 04:47 PM Riker Lauren Bullaro Senior Vice President, Finance Jul 05 '23 Sale 38.91 643 25,019 22,687 Jul 07 08:04 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 14 '23 Sale 38.42 6,366 244,606 22,687 Jun 16 05:39 PM Williams Kristen Marie Chief Administrative Officer Jun 14 '23 Sale 37.03 6,467 239,473 25,375 Jun 16 05:42 PM Kronenfeld Mark A. Director Jun 08 '23 Option Exercise 29.90 15,000 448,500 32,897 Jun 12 04:16 PM Kronenfeld Mark A. Director Jun 08 '23 Sale 37.04 15,000 555,600 17,897 Jun 12 04:16 PM STACK DAVID M CEO and Chairman Jun 07 '23 Sale 37.87 5,326 201,669 153,781 Jun 07 09:33 PM WINSTON ROY Chief Medical Officer Jun 07 '23 Sale 37.87 1,857 70,315 41,356 Jun 07 09:36 PM Reinhart Charles A. III Chief Financial Officer Jun 07 '23 Sale 37.87 1,371 51,913 33,626 Jun 07 09:29 PM Williams Kristen Marie Chief Administrative Officer Jun 07 '23 Sale 37.87 1,357 51,383 20,892 Jun 07 09:34 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 07 '23 Sale 37.87 1,162 43,999 30,909 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 07 '23 Sale 37.87 1,099 41,614 29,225 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 07 '23 Sale 37.87 1,057 40,023 38,115 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 07 '23 Sale 37.87 1,047 39,645 21,539 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 07 '23 Sale 37.87 616 23,325 19,053 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 07 '23 Sale 37.87 490 18,554 36,323 Jun 07 09:32 PM STACK DAVID M CEO and Chairman Jun 06 '23 Sale 38.99 5,058 197,216 159,107 Jun 07 09:33 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 06 '23 Sale 38.55 4,521 174,285 12,877 Jun 07 09:26 PM WINSTON ROY Chief Medical Officer Jun 06 '23 Sale 38.99 1,779 69,365 43,213 Jun 07 09:36 PM Williams Kristen Marie Chief Administrative Officer Jun 06 '23 Sale 38.99 1,301 50,727 22,249 Jun 07 09:34 PM Reinhart Charles A. III Chief Financial Officer Jun 06 '23 Sale 38.99 1,236 48,193 34,997 Jun 07 09:29 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 06 '23 Sale 38.99 1,114 43,436 32,071 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 06 '23 Sale 38.99 1,054 41,097 30,324 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 06 '23 Sale 38.99 1,014 39,537 39,172 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 06 '23 Sale 38.99 1,005 39,186 22,586 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 06 '23 Sale 38.99 591 23,044 19,669 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 06 '23 Sale 38.99 471 18,365 36,813 Jun 07 09:32 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 05 '23 Sale 38.28 2,267 86,774 17,398 Jun 07 09:26 PM GAUGLER DARYL Chief Operating Officer Jun 05 '23 Sale 38.74 1,000 38,740 23,591 Jun 07 09:22 PM Brege Laura Director Jun 05 '23 Sale 38.74 600 23,244 9,547 Jun 07 09:18 PM HASTINGS PAUL J Director Jun 05 '23 Sale 38.34 580 22,237 6,599 Jun 07 09:23 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Option Exercise 34.00 2,500 85,000 26,894 Jun 02 06:28 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Sale 39.08 2,500 97,700 24,591 Jun 02 06:28 PM HASTINGS PAUL J Director May 15 '23 Option Exercise 29.90 7,000 209,300 14,179 May 17 04:07 PM HASTINGS PAUL J Director May 15 '23 Sale 41.85 7,000 292,950 7,179 May 17 04:07 PM PACE GARY W Director May 11 '23 Option Exercise 29.90 7,000 209,300 144,690 May 15 06:53 PM PACE GARY W Director May 11 '23 Sale 41.78 5,015 209,527 139,675 May 15 06:53 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
